Most users transition to reduced maintenance doses rather than stopping entirely, which preserves 85 to 90 percent of peak weight loss long-term
It attacks the core drivers of type 2 diabetes: hepatic and peripheral insulin resistance, ectopic lipid accumulation, and compensatory hyperinsulinemia
GLP-1 receptor agonists work through several different mechanisms to help patients lose weight: delayed gastric emptying, increased satiety, inhibited release of glucagon aYer meals, and stimulation insulin release
Safety and Side Effect Profile Both compounds belong to the same general drug class and share a broadly similar side effect profile, largely gastrointestinal in nature
But when it comes to covering GLP-1s for obesity treatment, thats a different story
This third target, the glucagon receptor, is what makes retatrutide a fundamentally different research tool